SFM
CBAY

Sphera Funds Management’s Cymabay Therapeutics CBAY Stock Holding History

Sphera Funds Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-345,535
Closed -$4.59M – 114
2019
Q1 		$4.59M Buy
+345,535
New +$3.67M 0.42% 55
2018
Q1 		– Sell
-240,000
Closed -$2.21M – 150
2017
Q4 		$2.21M Buy
+240,000
New +$2.05M 0.26% 90
2015
Q2 		– Sell
-157,179
Closed -$1.09M – 162
2015
Q1 		$1.09M Sell
157,179
-233,176
-60% -$2.24M 0.11% 134
2014
Q4 		$3.84M Sell
390,355
-100,000
-20% -$804K 0.65% 49
2014
Q3 		$3.35M Buy
+490,355
New +$3.01M 0.41% 57

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Sphera Funds Management's CBAY Position: Q2 2019 in Review

Sphera Funds Management sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 345,535 shares — an estimated $4.59M sold.

Sphera Funds Management first reported a position in CBAY in Q3 2014 and held it in 5 quarters. The position peaked at $4.59M in Q1 2019. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

  • Sphera Funds Management reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Sphera Funds Management sold 345,535 Cymabay Therapeutics shares in Q2 2019, an estimated $4.59M.
  • Sphera Funds Management first reported a position in Cymabay Therapeutics in Q3 2014 and held it in 5 quarters.
  • Sphera Funds Management's Cymabay Therapeutics position peaked at $4.59M in Q1 2019.
  • 133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on Sphera Funds Management's 13F filing for Q2 2019, filed 14 Aug 2019.